Dupixent
E561777
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Dupixent canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T6006202 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Dupixent Context triple: [Sanofi, hasBrand, Dupixent]
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
E.
Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Dupixent Target entity description: Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
E.
Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ prescription drug ⓘ |
| hasActiveIngredient | dupilumab ⓘ |
| hasATCCode | L04AC13 ⓘ |
| hasBrandOwner |
Regeneron Pharmaceuticals
NERFINISHED
ⓘ
Sanofi NERFINISHED ⓘ |
| hasCommonSideEffect |
blepharitis
ⓘ
conjunctivitis ⓘ eosinophilia ⓘ injection site reactions ⓘ oral herpes ⓘ |
| hasDosageForm |
pre-filled pen
ⓘ
pre-filled syringe ⓘ |
| hasDrugClass |
immunomodulator
ⓘ
interleukin inhibitor ⓘ |
| hasFDAApprovalStatus | approved ⓘ |
| hasGenericName | dupilumab NERFINISHED ⓘ |
| hasPregnancyCategory | insufficient human data ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasTarget | type 2 inflammation pathway ⓘ |
| inhibitsPathway |
IL-13 signaling
ⓘ
IL-4 signaling ⓘ |
| isAdministeredBy | subcutaneous injection ⓘ |
| isAdministeredOn | every-other-week schedule ⓘ |
| isCoDevelopedBy | Sanofi NERFINISHED ⓘ |
| isContraindicatedIn | patients with known hypersensitivity to dupilumab ⓘ |
| isDevelopedBy | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| isIndicatedFor |
adults with chronic rhinosinusitis with nasal polyps
ⓘ
adults with eosinophilic esophagitis ⓘ adults with moderate-to-severe asthma ⓘ adults with moderate-to-severe atopic dermatitis ⓘ adults with prurigo nodularis ⓘ pediatric patients with moderate-to-severe asthma ⓘ pediatric patients with moderate-to-severe atopic dermatitis ⓘ |
| isNot |
a corticosteroid
ⓘ
a systemic immunosuppressant ⓘ |
| targetsMolecule | interleukin-4 receptor alpha NERFINISHED ⓘ |
| treatsCondition |
asthma
ⓘ
atopic dermatitis ⓘ chronic rhinosinusitis with nasal polyps ⓘ chronic spontaneous urticaria ⓘ eosinophilic asthma ⓘ eosinophilic esophagitis ⓘ moderate-to-severe asthma ⓘ moderate-to-severe atopic dermatitis ⓘ oral corticosteroid-dependent asthma ⓘ prurigo nodularis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Dupixent Description of subject: Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.